Income statement, balance sheet and cash flow statement for the last 5 fiscal years, taken from the XBRL data Bioquest Corp files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2014
FY2014
FY2021
FY2021
FY2022
Revenue
0
0
General and administrative
0.01
0.12
0.02
0.11
0.06
Operating expenses
0.36
2.2
0.82
Operating income
-0.01
-0.12
-0.36
-2.2
-0.82
Interest expense
0
0.04
0.03
Other non-operating income
0
-0.36
Income tax
0
0
Net income
-0.01
-0.49
-0.36
-2.32
-0.82
EBITDA
-0.01
-0.12
EPS, basic
0.00
-0.03
-0.28
-0.87
-0.08
EPS, diluted
0.00
-0.03
-0.28
-0.28
-0.08
Shares, basic (weighted)
16.8
17.4
1.32
2.66
Shares, diluted (weighted)
16.8
17.4
1.32
2.66
10.1
Balance sheet
FY2014
FY2014
FY2021
FY2021
FY2022
Cash and equivalents
0.01
0.54
0
0
0.03
Receivables
0
Inventory
0
0
Other current assets
0
0
0.02
Total current assets
0.01
0.89
0
0.02
0.03
Property, plant and equipment
0
0
Goodwill
0
Intangible assets
0
Total assets
0.01
0.89
0
0.02
0.03
Accounts payable
0
0.01
0.02
0.17
0.18
Accrued liabilities
0
0.07
1.37
Total current liabilities
0
0.01
0.1
1.79
0.47
Long-term debt
0.04
Total liabilities
0
0.01
0.14
1.79
0.47
Paid-in capital
-0.03
-0.03
7.32
8.07
10
Retained earnings
-0.01
-0.5
-7.52
-9.84
-10.7
Other comprehensive income
0
-7.52
Shareholders' equity
0.01
0.88
-0.14
-1.77
-0.43
Total equity
0.01
0.88
-0.14
-1.77
-0.43
Total liabilities and equity
0.01
0.89
0
0.02
0.03
Shares outstanding
17.4
17.4
2.59
2.81
11.3
Cash flow statement
FY2014
FY2014
FY2021
FY2021
FY2022
Net income
-0.01
-0.49
-0.36
-2.32
-0.82
Depreciation and amortization
0
0
Stock-based compensation
0.12
0.53
0.21
Deferred income tax
-0.08
-0.08
Change in payables
0
0.01
0.04
0.16
0.01
Cash from operations
-0.01
-0.47
-0.12
-0.19
-0.12
Cash from investing
0
0
Stock issued
0.01
0
0.06
0.14
0.07
Cash from financing
0.01
1.01
0.13
0.19
0.15
Net change in cash
0.01
0.54
0
0
0.03
Interest paid
0
0
Income taxes paid
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to July 31, 2022; growth uses fiscal years. Valuation uses the share price of $0.07 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-3,393.0%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
96.2%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
280.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.03x
Current assets / current liabilities.
Quick ratio
0.03x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.03x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.01
Cash from operations / diluted weighted shares.
Book value per share
-$0.05
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
Earnings yield
-0.1%
Net income / market cap (the inverse of P/E).
Was Bioquest Corp profitable in fiscal 2022?
No. It reported a net loss of $821.0K.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.